By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Micromet AG 

Am Klopferspitz 19

Martinsried  Planegg  82152  Germany
Phone: 49-0-89-895277-0 Fax: +49-0-89-895277-22



Drug Delivery



Company News
Amgen (AMGN) Completes Tender Offer for Outstanding Shares of Micromet 3/7/2012 10:04:51 AM
Amgen (AMGN) Announces Initial Results of Tender Offer for Outstanding Shares of Micromet and Commencement of Subsequent Offering Period 3/5/2012 9:59:10 AM
Buyout Offer for Micromet Triggers Shareholder-Claim Investigation by Goldfarb LLP Securities Attorneys 2/6/2012 9:30:56 AM
Micromet Signs CRADA with National Cancer Institute to Expand Development of Blinatumomab 1/9/2012 6:35:48 AM
Micromet’s Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma Patients 12/12/2011 7:49:18 AM
Micromet Appoints Joseph Lobacki Senior Vice President and Chief Commercial Officer 12/5/2011 6:23:09 AM
Micromet Initiates Global Phase 2 Trial of Blinatumomab in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia 11/28/2011 10:25:44 AM
Micromet to Present at the 2011 Piper Jaffray Health Care Conference 11/23/2011 10:11:26 AM
Micromet Reports Third Quarter 2011 Financial Results 11/8/2011 7:18:33 AM
Micromet to Report Blinatumomab Data at 2011 American Society of Hematology Annual Meeting 11/8/2011 7:12:52 AM